Prevail IPO Aims to Conquer Parkinson’s

Formed by OrbiMed, the Silverstein Foundation for Parkinson's with GBA, and a Columbia University neurologist, Prevail (PRVL) is applying gene therapies to genetic

subsets of neurodegenerative diseases, including Parkinson's Disease (PD). It’s using the same technology deployed by Novartis in their recently approved super expensive ($2 million) therapy Zolgensma for spinal muscular atrophy for infants.

Here are three other things you need to know about Prevail.

To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.